Filtered By:
Drug: Rituxan
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 5210 results found since Jan 2013.
New approaches for managing antiphospholipid syndrome
Nat Clin Pract Rheumatol. 2009 Mar;5(3):160-70. doi: 10.1038/ncprheum1017.ABSTRACTAntiphospholipid antibodies (aPL) are a family of autoantibodies directed against phospholipid-binding plasma proteins, most commonly beta(2)-glycoprotein-I. Primary thrombosis prevention in persistently aPL-positive individuals requires a risk-stratified approach; elimination of reversible thrombosis risk factors and aggressive prophylaxis during high-risk periods are crucial. The effectiveness of aspirin in persistently aPL-positive patients without vascular involvement is not supported by data from prospective, controlled studies. For the ...
Source: Nature Clinical Practice. Rheumatology. - March 3, 2009 Category: Rheumatology Authors: Doruk Erkan Michael D Lockshin Source Type: research
Vaccination against SARS-CoV-2 in patients with multiple sclerosis
CONCLUSION: The data available make it possible to recommend mRNA vaccines against SARS-CoV-2 in patients with multiple sclerosis. In patients on fingolimod, cladribine, alemtuzumab, ocrelizumab and rituximab, vaccination prior to the initiation of medication administration would be recommendable whenever possible.PMID:33764494 | DOI:10.33588/rn.7207.2021097
Source: Revista de Neurologia - March 25, 2021 Category: Neurology Authors: L Costa Frossard-Fran ça J M Garc ía-Domínguez I Moreno-Torres J Fort ún L M Villar V Meca-Lallana Source Type: research
